Since active hepatitis B virus (HBV) replication is the key driver of hepatic necroinflammation
and disease progression, the treatment aim of chronic hepatitis B (CHB) is to suppress HBV …

Aims The Korean Association for the Study of the Liver (KASL) Practice Guidelines for
Management of Hepatitis C were first established in 2004, and revised in 2013, when direct …

Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest
rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection …

A<fc>ASLD</fc> guidelines for treatment of chronic hepatitis <fc>B</fc> Page 1 PRACTICE
GUIDELINE AASLD Guidelines for Treatment of Chronic Hepatitis B Norah A. Terrault,1 Natalie …

Our understanding of the natural history of hepatitis B virus (HBV) infection and the potential
for therapy of the resultant disease is continuously improving. New data have become …

Large volume of new data on the natural history and treatment of chronic hepatitis B virus
(HBV) infection have become available since 2008. These include further studies in …

Background Long-term tenofovir disoproxil fumarate (TDF) treatment for chronic hepatitis B
(CHB) is associated with sustained viral suppression and regression of fibrosis and cirrhosis …

临床上广泛使用的一线抗HBV 药物核苷(酸) 类似物(NAs) 可有效地抑制HBV DNA 复制,
显著减缓慢性乙型肝炎(CHB) 患者的疾病进展, 减少包括肝衰竭和肝癌在内的终末期肝病的发生 …

The long‐term clinical impact of low‐level viremia (LLV;< 2,000 IU/mL) is not well
understood. As a result, it is unclear whether the development of LLV during entecavir …

Background & Aims Chronic hepatitis B (CHB) infection remains the most frequent etiology
of hepatocellular carcinoma globally as well as a major cause of cirrhosis. Despite …